Arbutus Biopharma Corporation (ABUS) Stock

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation is led by CEO Lindsay Androski, employs 44 people, headquartered in US, publicly traded since 2007.

Arbutus Biopharma Corporation (ABUS) stock trades at $4.20 with a market capitalization of $832.04M. The stock is valued at a price-to-earnings (P/E) ratio of 5.63, price-to-book of 3.40, price-to-sales of 4.84. Over the past 52 weeks the stock has ranged between $3.50 and $5.45, and currently trades 22.9% below its 52-week high.

On profitability, Arbutus Biopharma Corporation generates a return on equity (ROE) of 90.98%, above the typical market range of roughly 12-15%, return on capital employed of 54.39%, an operating margin of -192.86%, a net profit margin of 84.23%.

Arbutus Biopharma Corporation by the numbers, 2016–2025

Between 2016 and 2025 Arbutus Biopharma Corporation reported revenue of $2.0M rising to $14.0M, a change of +600.0% across 10 years. Compounded, revenue has grown 14.9% a year over five years, -28.9% over three, 133.3% over the last twelve months. Net profit rose to $-34.0M.

Operating margin went from -32773.3% in 2016 to -192.1% in 2025, a gain of 32581.3 percentage points. The most recent net margin is 84.23%. On a trailing twelve-month basis to Jun '26, revenue is $182.0M and net profit $153.0M.

Borrowings fell from $12.0M to $4.0M, cash from operations was $-40.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -56.1% over five years, and was -44.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Arbutus Biopharma Corporation (ABUS) — frequently asked questions